Limited benefit of molecular profiling in patients with
low-grade endometrial cancer

a 2022

Limited benefit of molecular profiling in patients with low-grade endometrial cancer

VREDE, S, J KASIUS, J BULTEN, J VAN WEELDEN W, D BOLL et. al.

Základní údaje

Originální název

Limited benefit of molecular profiling in patients with low-grade endometrial cancer

Autoři

Vydání

ESMO Gynaecological Cancers Congress,Valencia, Spain, 17-18 June 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.annonc.2022.04.039

UT WoS

000814982500022

Příznaky

Mezinárodní význam

Změněno: 22. 11. 2022 11:30, Mgr. Tereza Miškechová

Anotace

V originále

Background Most patients present with low-grade (grade 1-2) early-stage (FIGO I-II) endometrioid EC (EEC), it is questioned whether these patients benefit from molecular profiling. We aim to investigate the prognostic relevance of molecular profiling within low-grade EEC. Methods A retrospective multicenter study within the European Network for Individualized Treatment (ENITEC) network. Patients with early-stage EC were excluded if lymph node status was unknown. Molecular profiling was conducted using single-molecule Molecular Inversion Probes based on Next Generation Sequencing. Subsequently, cases were classified as: polymerase epsilon (POLE) mutant, microsatellite instable (MSI), tumor protein (TP53) mutation and no-specific molecular profile (NSMP). Results Total of 393 EC patients were included, 75% had early-stage EC, and 54% low-grade EEC. Of all patients, 8.1% was classified as POLEmut, 16.8% as MSI, 21.4% as TP53-mutated and 53.7% as NSMP. Median follow-up was 5.3-years. Across all molecular subgroups, patients with low-grade EEC had superior disease-specific survival (DSS) compared to high-grade (grade 3) EC, respectively >89% vs. >43%. Equally, patients with low-grade EEC had improved recurrence-free survival (RFS) compared to high-grade EC within POLEmut, MSI and NSMP. Within TP53-mutated, only grade 1 EEC showed an excellent RFS (92%) when compared to grade 2 (54%) and grade 3 EC (44%). In multivariate analysis that included age, lymphovascular space invasion, grade, FIGO stage and the four molecular subgroups, TP53-mutated, high-grade and advanced-stage (FIGO III-IV) remained independent prognostic factors for reduced DSS and RFS (respectively, hazard ratio (HR) 9.20 (95%-CI 1.23-68.90) p=0.031, HR 5.91 (95%-CI 2.63-13.28) p<0.001, HR 3.02 (95%-CI 1.61-5.62) p<0.001 and respectively, HR 12.27 (95%-CI 1.66-90.78) p=0.014, HR 2.66 (95%-CI 1.54-4.57) p<0.001, HR 2.58 (95%-CI 1.56-4.24) p<0.001). Conclusions Patients with grade 1 EEC have an excellent prognostic outcome across all molecular subgroups. In patients with grade 2 EEC, TP53-mutated seems to be prognostic relevant. Based on current data, routine molecular profiling in patients with low-grade EEC has shown limited contributive value to prognostic outcome.

Citovat

VREDE, S, J KASIUS, J BULTEN, J VAN WEELDEN W, D BOLL, M C VOS, A VAN ALTENA, X MATIAS-GUIU, J ASBERGER, E COLAS, A GIL-MORENO, J HUVILA, Vít WEINBERGER, F AMANT, M SNIJDERS, H KUSTERS-VANDEVELDE, A EIJKELENBOOM, R KRUITWAGEN, C REIJNEN a J M PIJNENBORG. Limited benefit of molecular profiling in patients with low-grade endometrial cancer. In ESMO Gynaecological Cancers Congress,Valencia, Spain, 17-18 June 2022. 2022. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2022.04.039.

@proceedings{2233440,
   author = {Vrede, S and Kasius, J and Bulten, J and Van Weelden W, J and Boll, D and Vos, M C and Van Altena, A and MatiasandGuiu, X and Asberger, J and Colas, E and GilandMoreno, A and Huvila, J and Weinberger, Vít and Amant, F and Snijders, M and KustersandVandevelde, H and Eijkelenboom, A and Kruitwagen, R and Reijnen, C and Pijnenborg, J M},
   booktitle = {ESMO Gynaecological Cancers Congress,Valencia, Spain, 17-18 June 2022},
   doi = {http://dx.doi.org/10.1016/j.annonc.2022.04.039},
   language = {eng},
   title = {Limited benefit of molecular profiling in patients with low-grade endometrial cancer},
   url = {https://www.annalsofoncology.org/article/S0923-7534(22)00724-4/fulltext},
   year = {2022}
}

TY  - CONF
ID  - 2233440
AU  - Vrede, S - Kasius, J - Bulten, J - Van Weelden W, J - Boll, D - Vos, M C - Van Altena, A - Matias-Guiu, X - Asberger, J - Colas, E - Gil-Moreno, A - Huvila, J - Weinberger, Vít - Amant, F - Snijders, M - Kusters-Vandevelde, H - Eijkelenboom, A - Kruitwagen, R - Reijnen, C - Pijnenborg, J M
PY  - 2022
TI  - Limited benefit of molecular profiling in patients with low-grade endometrial cancer
UR  - https://www.annalsofoncology.org/article/S0923-7534(22)00724-4/fulltext
N2  - Background Most patients present with low-grade (grade 1-2) early-stage (FIGO I-II) endometrioid EC (EEC), it is questioned whether these patients benefit from molecular profiling. We aim to investigate the prognostic relevance of molecular profiling within low-grade EEC. Methods A retrospective multicenter study within the European Network for Individualized Treatment (ENITEC) network. Patients with early-stage EC were excluded if lymph node status was unknown. Molecular profiling was conducted using single-molecule Molecular Inversion Probes based on Next Generation Sequencing. Subsequently, cases were classified as: polymerase epsilon (POLE) mutant, microsatellite instable (MSI), tumor protein (TP53) mutation and no-specific molecular profile (NSMP). Results Total of 393 EC patients were included, 75% had early-stage EC, and 54% low-grade EEC. Of all patients, 8.1% was classified as POLEmut, 16.8% as MSI, 21.4% as TP53-mutated and 53.7% as NSMP. Median follow-up was 5.3-years. Across all molecular subgroups, patients with low-grade EEC had superior disease-specific survival (DSS) compared to high-grade (grade 3) EC, respectively >89% vs. >43%. Equally, patients with low-grade EEC had improved recurrence-free survival (RFS) compared to high-grade EC within POLEmut, MSI and NSMP. Within TP53-mutated, only grade 1 EEC showed an excellent RFS (92%) when compared to grade 2 (54%) and grade 3 EC (44%). In multivariate analysis that included age, lymphovascular space invasion, grade, FIGO stage and the four molecular subgroups, TP53-mutated, high-grade and advanced-stage (FIGO III-IV) remained independent prognostic factors for reduced DSS and RFS (respectively, hazard ratio (HR) 9.20 (95%-CI 1.23-68.90) p=0.031, HR 5.91 (95%-CI 2.63-13.28) p<0.001, HR 3.02 (95%-CI 1.61-5.62) p<0.001 and respectively, HR 12.27 (95%-CI 1.66-90.78) p=0.014, HR 2.66 (95%-CI 1.54-4.57) p<0.001, HR 2.58 (95%-CI 1.56-4.24) p<0.001). Conclusions Patients with grade 1 EEC have an excellent prognostic outcome across all molecular subgroups. In patients with grade 2 EEC, TP53-mutated seems to be prognostic relevant. Based on current data, routine molecular profiling in patients with low-grade EEC has shown limited contributive value to prognostic outcome.
ER  -

VREDE, S, J KASIUS, J BULTEN, J VAN WEELDEN W, D BOLL, M C VOS, A VAN ALTENA, X MATIAS-GUIU, J ASBERGER, E COLAS, A GIL-MORENO, J HUVILA, Vít WEINBERGER, F AMANT, M SNIJDERS, H KUSTERS-VANDEVELDE, A EIJKELENBOOM, R KRUITWAGEN, C REIJNEN a J M PIJNENBORG. Limited benefit of molecular profiling in patients with low-grade endometrial cancer. In \textit{ESMO Gynaecological Cancers Congress,Valencia, Spain, 17-18 June 2022}. 2022. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2022.04.039.

Podrobný výpis o publikaci